Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning. Zacks Investment Research currently has $35.00 price target on the stock.
According to Zacks, “Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. “
DCPH has been the topic of several other reports. Leerink Swann assumed coverage on shares of Deciphera Pharmaceuticals in a report on Monday, September 24th. They set an underperform rating and a $28.00 target price on the stock. Canaccord Genuity set a $55.00 target price on shares of Deciphera Pharmaceuticals and gave the stock a buy rating in a report on Monday, August 13th. ValuEngine raised shares of Deciphera Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, October 2nd. Raymond James assumed coverage on shares of Deciphera Pharmaceuticals in a report on Wednesday, August 29th. They set an outperform rating and a $47.00 target price on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of Deciphera Pharmaceuticals in a report on Wednesday, August 22nd. They set an overweight rating and a $53.00 target price on the stock. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $47.55.
Shares of DCPH traded up $0.07 during mid-day trading on Tuesday, hitting $28.15. 182,171 shares of the company’s stock were exchanged, compared to its average volume of 197,186. Deciphera Pharmaceuticals has a 52 week low of $15.15 and a 52 week high of $45.61. The stock has a market capitalization of $1.46 billion and a PE ratio of -9.41. The company has a current ratio of 18.44, a quick ratio of 18.44 and a debt-to-equity ratio of 0.05.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Tuesday, August 7th. The company reported ($0.65) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.03. Equities research analysts predict that Deciphera Pharmaceuticals will post -2.61 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in DCPH. Bank of America Corp DE increased its stake in Deciphera Pharmaceuticals by 316.1% in the second quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock valued at $103,000 after acquiring an additional 1,982 shares during the last quarter. SG Americas Securities LLC bought a new position in Deciphera Pharmaceuticals in the first quarter valued at approximately $152,000. New York State Common Retirement Fund increased its stake in Deciphera Pharmaceuticals by 37.5% in the first quarter. New York State Common Retirement Fund now owns 9,900 shares of the company’s stock valued at $198,000 after acquiring an additional 2,700 shares during the last quarter. Trexquant Investment LP acquired a new stake in Deciphera Pharmaceuticals in the second quarter valued at approximately $203,000. Finally, Rhumbline Advisers acquired a new stake in Deciphera Pharmaceuticals in the second quarter valued at approximately $301,000. 53.53% of the stock is currently owned by institutional investors and hedge funds.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Recommended Story: Hedge Funds – Risk or Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.